390 related articles for article (PubMed ID: 19171131)
1. Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice.
Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
Eur J Pharmacol; 2009 Mar; 605(1-3):170-6. PubMed ID: 19171131
[TBL] [Abstract][Full Text] [Related]
2. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Shiraki K; Hayakawa M; Shibasaki M
Metabolism; 2009 Mar; 58(3):379-86. PubMed ID: 19217455
[TBL] [Abstract][Full Text] [Related]
3. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.
Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
Pharmacol Rep; 2009; 61(5):899-908. PubMed ID: 19904014
[TBL] [Abstract][Full Text] [Related]
4. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity.
Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Nagase I; Hayakawa M; Shibasaki M
Biochem Pharmacol; 2008 Jul; 76(1):98-107. PubMed ID: 18468582
[TBL] [Abstract][Full Text] [Related]
5. Hypoglycaemic effects of antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic rats.
Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Shibasaki M
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):560-8. PubMed ID: 18793271
[TBL] [Abstract][Full Text] [Related]
6. Effects of antidiabetic drugs on glucose tolerance in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic mice.
Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Shibasaki M
Horm Metab Res; 2008 Dec; 40(12):880-6. PubMed ID: 18819058
[TBL] [Abstract][Full Text] [Related]
7. Effects of the dipeptidyl peptidase-IV inhibitor ASP8497 on glucose tolerance in animal models of secondary failure.
Someya Y; Nakano R; Tahara A; Takasu T; Takeuchi A; Nagase I; Matsuyama-Yokono A; Hayakawa M; Sasamata M; Miyata K; Uchiyama Y
Eur J Pharmacol; 2009 Nov; 622(1-3):71-7. PubMed ID: 19766107
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice.
Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
Pharmacology; 2009; 83(3):177-87. PubMed ID: 19176982
[TBL] [Abstract][Full Text] [Related]
9. Effects of antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice.
Tahara A; Matsuyama-Yokono A; Shibasaki M
Eur J Pharmacol; 2011 Mar; 655(1-3):108-16. PubMed ID: 21266174
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.
Someya Y; Tahara A; Nakano R; Matsuyama-Yokono A; Nagase I; Fukunaga Y; Takasu T; Hayakawa M; Shibasaki M
Naunyn Schmiedebergs Arch Pharmacol; 2008 May; 377(3):209-17. PubMed ID: 18398600
[TBL] [Abstract][Full Text] [Related]
11. Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice.
Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
Naunyn Schmiedebergs Arch Pharmacol; 2009 Feb; 379(2):191-9. PubMed ID: 18762913
[TBL] [Abstract][Full Text] [Related]
12. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
Arch Pharm Res; 2016 Feb; 39(2):259-270. PubMed ID: 26450351
[TBL] [Abstract][Full Text] [Related]
13. Reduction of oxidative stress by a new low-molecular-weight antioxidant improves metabolic alterations in a nonobese mouse diabetes model.
Novelli M; D'Aleo V; Lupi R; Paolini M; Soleti A; Marchetti P; Masiello P
Pancreas; 2007 Nov; 35(4):e10-7. PubMed ID: 18090226
[TBL] [Abstract][Full Text] [Related]
14. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
[TBL] [Abstract][Full Text] [Related]
15. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
16. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
Asakawa T; Moritoh Y; Kataoka O; Suzuki N; Takeuchi K; Odaka H
Life Sci; 2009 Jul; 85(3-4):122-6. PubMed ID: 19427871
[TBL] [Abstract][Full Text] [Related]
17. Effects of the combination of a dipeptidyl peptidase IV inhibitor and an insulin secretagogue on glucose and insulin levels in mice and rats.
Yamazaki K; Yasuda N; Inoue T; Yamamoto E; Sugaya Y; Nagakura T; Shinoda M; Clark R; Saeki T; Tanaka I
J Pharmacol Exp Ther; 2007 Feb; 320(2):738-46. PubMed ID: 17093132
[TBL] [Abstract][Full Text] [Related]
18. Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice.
Roy S; Khanna V; Mittra S; Dhar A; Singh S; Mahajan DC; Priyadarsiny P; Davis JA; Sattigeri J; Saini KS; Bansal VS
Life Sci; 2007 Jun; 81(1):72-9. PubMed ID: 17532347
[TBL] [Abstract][Full Text] [Related]
19. Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
Arulmozhi DK; Kurian R; Bodhankar SL; Veeranjaneyulu A
J Pharm Pharmacol; 2008 Sep; 60(9):1167-73. PubMed ID: 18718120
[TBL] [Abstract][Full Text] [Related]
20. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
